Search results for "NUDE-MICE"

showing 2 items of 2 documents

Myc Promoter-Binding Protein-1 (MBP-1) Is a Novel Potential Prognostic Marker in Invasive Ductal Breast Carcinoma

2010

BackgroundAlpha-enolase is a glycolytic enzyme that catalyses the formation of phosphoenolpyruvate in the cell cytoplasm. α-Enolase and the predominantly nuclear Myc promoter-binding protein-1 (MBP-1) originate from a single gene through the alternative use of translational starting sites. MBP-1 binds to the P2 c-myc promoter and competes with TATA-box binding protein (TBP) to suppress gene transcription. Although several studies have shown an antiproliferative effect of MBP-1 overexpression on several human cancer cells, to date detailed observations of α-enolase and MBP-1 relative expression in primary tumors versus normal tissues and their correlation with clinicopathological features ha…

CytoplasmAlpha-enolasePROGRESSIONAged 80 and overRegulation of gene expressionMultidisciplinaryQRGenetics and Genomics/Gene ExpressionMiddle AgedPrognosisPathology/Molecular PathologyNUDE-MICETransport proteinCarcinoma DuctalDNA-Binding ProteinsGene Expression Regulation NeoplasticProtein Transportmedicine.anatomical_structureGLYCOLYTIC ENZYMEOncology/Breast CancerMedicineCELL LUNG-CANCER; ALPHA-ENOLASE; PROTEOMIC ANALYSIS; GLYCOLYTIC ENZYME; NUDE-MICE; GENE; IDENTIFICATION; PROGRESSION; EXPRESSION; METASTASESFemalePROTEOMIC ANALYSISEnolase MBP-1 Breast cancer ImmunohistochemistryResearch ArticleAdultEXPRESSIONScienceCELL LUNG-CANCERBreast NeoplasmsBiologyDNA-binding proteinBiomarkers TumormedicineHumansNeoplasm InvasivenessGeneAgedCell NucleusIDENTIFICATIONBinding proteinALPHA-ENOLASEGENEMolecular biologySettore BIO/18 - GeneticaCell nucleusMETASTASESCytoplasmPhosphopyruvate Hydratasebiology.proteinPLoS ONE
researchProduct

89 Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89 Zr Radiochemistry

2017

Contains fulltext : 181624.pdf (Publisher’s version ) (Open Access) Immuno-positron emission tomography (immunoPET) with (89)Zr-labeled antibodies has shown great potential in cancer imaging. It can provide important information about the pharmacokinetics and tumor-targeting properties of monoclonal antibodies and may help in anticipating on toxicity. Furthermore, it allows accurate dose planning for individualized radioimmunotherapy and may aid in patient selection and early-response monitoring for targeted therapies. The most commonly used chelator for (89)Zr is desferrioxamine (DFO). Preclinical studies have shown that DFO is not an ideal chelator because the (89)Zr-DFO complex is partly…

Pathologymedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentmonoclonal-antibodiesBiomedical Engineeringrational designPharmaceutical Sciencebifunctional chelating-agentBioengineeringCancer imagingReviewgrowth-factorRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]010402 general chemistryMonoclonal antibody01 natural sciencesDose planningp-isothiocyanatobenzyl-desferrioxamineIn vivo[ CHIM.ORGA ] Chemical Sciences/Organic chemistryimmuno-petmedicineIn patient[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyPharmacologymedicine.diagnostic_test010405 organic chemistrybusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryOrganic Chemistrydrug development3. Good health0104 chemical sciencesDrug developmentPositron emission tomographyRadioimmunotherapyUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]click chemistryCancer researchmetastatic breast-cancerbusinessbearing nude-miceNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]BiotechnologyBioconjugate Chemistry
researchProduct